TA
BMRN icon

Tamarack Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

Tamarack Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,500
Closed -$23K – 50
2021
Q3 		$23K Buy
+1,500
New +$118K 0.01% 45

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Tamarack Advisers's BMRN Position: Q3 2023 in Review

Tamarack Advisers sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 75,000 shares — an estimated $6.5M sold.

Tamarack Advisers first reported a position in BMRN in Q4 2021 and held it in 4 quarters. The position peaked at $7.95M in Q4 2021. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

  • Tamarack Advisers reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Tamarack Advisers sold 75,000 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $6.5M.
  • Tamarack Advisers first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 4 quarters.
  • Tamarack Advisers's BioMarin Pharmaceuticals position peaked at $7.95M in Q4 2021.
  • 519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Tamarack Advisers's 13F filing for Q3 2023, filed 16 Nov 2023.